2020年欧洲癌症终生患病率按病程和国家的完整估计(EUROCARE-6):一项基于人群的研究
该研究利用61个癌症登记处截至2013年1月1日的发病和随访数据,采用完整性指数法估计了2020年欧洲29国及欧盟27国32种恶性肿瘤的完整和限时患病率,并做线性回归预测。2010至2020年间患病人数年均增长3.5%(总体41%),部分归因于人口老龄化。
要点
- 2010至2020年患病人数年均增长3.5%(总体41%),部分因人口老龄化。
核心结论
- 研究结果有助于欧洲国家层面制定循证政策,改善癌症患者全病程的生活质量、照护和康复。
- 未来工作包括按诊断时分期估计 prevalent cases 的治愈时间。
研究设计与样本
- 基于人群的研究,使用61个癌症登记处截至2013年1月1日的发病和随访数据。
- 采用完整性指数法估计29个欧洲国家和欧盟27国(由22个提供登记数据的成员国代表)按癌种、性别和年龄的完整及限时患病率。
- 聚焦依据国际肿瘤疾病分类第三版定义的32种恶性肿瘤,仅考虑第一原发肿瘤。
- 使用线性回归预测截至2020年1月1日的癌症患病比例。
主要发现
- 女性幸存者前五位肿瘤为乳腺癌、结直肠癌、子宫体癌、皮肤黑色素瘤和甲状腺癌(粗患病比例从每10万2270例[95%CI 2248–2292]至每10万301例[95%CI 297–305])。
- 男性幸存者最常见肿瘤为前列腺癌、结直肠癌、膀胱癌、皮肤黑色素瘤和肾癌(从每10万1714例[95%CI 1686–1741]至每10万255例[95%CI 249–260])。
- 国家间患病率差异大(按癌种不同为2至10倍),与人口结构、发病率和生存模式一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer survivors-people living with and beyond cancer-are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6 study. METHODS: In this population-based study, using incidence and follow-up data up to Jan 1, 2013, from 61 cancer registries, complete and limited-duration prevalence by cancer type, sex, and age were estimated for 29 European countries and the 27 countries in the EU (EU27; represented by 22 member states that contributed registry data) using the completeness index method. We focused on 32 malignant cancers defined according to the third edition of the International Classification of Diseases for Oncology, and only the first primary tumour was considered when estimating the prevalence. Prevalence measures are expressed in terms of absolute number of prevalent cases, crude prevalence proportion (reported as percentage or cases per 100 000 resident people), and age-standardised prevalence proportion based on the European Standard Population 2013. We made projections of cancer prevalence proportions up to Jan 1, 2020, using linear regression. FINDINGS: In 2020, 23 711 thousand (95% CI 23 565-23 857) people (5·0% of the population) were estimated to be alive after a cancer diagnosis in Europe, and 22 347 thousand (95% CI 22 210-22 483) in EU27. Cancer survivors were more frequently female (12 818 thousand [95% CI 12 720-12 917]) than male (10 892 thousand [10 785-11 000]). The five leading tumours in female survivors were breast cancer, colorectal cancer, corpus uterine cancer, skin melanoma, and thyroid cancer (crude prevalence proportion from 2270 [95%CI 2248-2292] per 100 000 to 301 [297-305] per 100 000). Prostate cancer, colorectal cancer, urinary bladder cancer, skin melanoma, and kidney cancer were the most common tumours in male survivors (from 1714 [95% CI 1686-1741] per 100 000 to 255 [249-260] per 100 000). The differences in prevalence between countries were large (from 2 to 10 times depending on cancer type), in line with the demographic structure, incidence, and survival patterns. Between 2010 and 2020, the number of prevalent cases increased by 3·5% per year (41% overall), partly due to an ageing population. In 2020, 14 850 thousand (95% CI 14 681-15 018) people were estimated to be alive more than 5 years after diagnosis and 9099 thousand (8909-9288) people were estimated to be alive more than 10 years after diagnosis, representing an increasing proportion of the cancer survivor population. INTERPRETATION: Our findings are useful at the country level in Europe to support evidence-based policies to improve the quality of life, care, and rehabilitation of patients with cancer throughout the disease pathway. Future work includes estimating time to cure by stage at diagnosis in prevalent cases. FUNDING: European Commission.
引用
- De Angelis R, Demuru E, Baili P, et al. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024. PMID: 38307102. doi:10.1016/S1470-2045(23)00646-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。